Analyse de rentabilité
Sur le marché chinois en pleine expansion des diagnostics moléculaires, notre client, une entreprise de premier plan dans le domaine de l'équipement médical, s'est trouvé confronté à un litige portant sur des accords de coentreprise, de licence et de fabrication, déclenché par l'acquisition du défendeur par une entreprise américaine de diagnostics. Notre client envisageait de lancer une procédure d'arbitrage.
Since the joint venture had not yet started commercial operations, our model assumptions were primarily based on the contemporaneous business plans. We dedicated a significant amount of effort to validating the reliability of the business plans and applying assumptions to the model. Additionally, given the cutting-edge nature of the molecular diagnostics technology involved (PCR), we conducted extensive research, competitor benchmarking and interviews with our client’s R&D staff to make our initial calculation and analysis more robust.
We were engaged as the quantum expert to review the sunk costs and provide an assessment of the lost profit claim to be pursued in the arbitration. Our initial assessment of the lost profit at c. USD 60m was based on contemporaneous business plans with certain adjustments. This preliminary assessment facilitated focused discussions between the parties, ultimately resulting in a settlement after the commencement of the arbitration proceedings.